First U.K. Patient Receives Trial Drug as Treatment for Covid-19
First U.K. Patient Receives Trial Drug as Treatment for Covid-19
DJ First U.K. Patient Receives Trial Drug as Treatment for Covid-19
By Adriano Marchese
The first U.K. patient has been treated with an experimental drug for severe lung disease related to Covid-19, the Manchester University NHS Foundation Trust said Monday.
The patient is part of the Oscar study conducted by U.K. pharmaceutical giant GlaxoSmithKline PLC, set up to investigate whether one of its pipeline drugs, Otilimab, can help reduce the effects of the so-called cytokine storm--a severe immune reaction where the body starts to attack its own cells--which was found to occur in some hospitalized Covid-19 patients.
The drug is a monoclonal antibody that was already in late-stage clinical trials and was originally considered as a potential new treatment for rheumatoid arthritis.
The patient is being treated at the Manchester Royal Infirmary, part of the Manchester University NHS Foundation Trust, and was recruited to the study on Sept. 11.
The Oscar study, which stands for Otilimab in Severe Covid-19-Related Disease, is sponsored and funded by GlaxoSmithKline and is one of several studies that received the urgent public-health research status by the U.K.'s Department of Health and Social Care.
The study is planned to be extended to more hospitals across the U.K., the Manchester University NHS Foundation Trust said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
September 27, 2020 19:01 ET (23:01 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
DJ First U.K. Patient Receives Trial Drug as Treatment for Covid-19
DJ首例英國患者接受試驗藥物治療新冠肺炎
By Adriano Marchese
阿德里亞諾·馬爾切斯(Adriano Marchese)
The first U.K. patient has been treated with an experimental drug for severe lung disease related to Covid-19, the Manchester University NHS Foundation Trust said Monday.
週一，曼徹斯特大學NHS基金會信託基金表示，英國第一名患者已經接受了一種治療與新冠肺炎有關的嚴重肺部疾病的實驗性藥物的治療。
The patient is part of the Oscar study conducted by U.K. pharmaceutical giant GlaxoSmithKline PLC, set up to investigate whether one of its pipeline drugs, Otilimab, can help reduce the effects of the so-called cytokine storm--a severe immune reaction where the body starts to attack its own cells--which was found to occur in some hospitalized Covid-19 patients.
這名患者是英國製藥巨頭葛蘭素史克公司(GlaxoSmithKline PLC)進行的奧斯卡研究的一部分，該研究成立的目的是調查其流水線藥物之一奧蒂利馬(Otilimab)是否有助於減少所謂的細胞因子風暴的影響。細胞因子風暴是一種嚴重的免疫反應，身體開始攻擊自己的細胞。在一些住院的新冠肺炎患者中發現了這種反應。
The drug is a monoclonal antibody that was already in late-stage clinical trials and was originally considered as a potential new treatment for rheumatoid arthritis.
該藥物是一種單克隆抗體，已經處於後期臨牀試驗階段，最初被認為是治療類風濕性關節炎的潛在新療法。
The patient is being treated at the Manchester Royal Infirmary, part of the Manchester University NHS Foundation Trust, and was recruited to the study on Sept. 11.
這名患者目前正在曼徹斯特皇家醫院接受治療，該醫院是曼徹斯特大學NHS基金會信託基金的一部分，並於9月9日被招募到這項研究中。11.
The Oscar study, which stands for Otilimab in Severe Covid-19-Related Disease, is sponsored and funded by GlaxoSmithKline and is one of several studies that received the urgent public-health research status by the U.K.'s Department of Health and Social Care.
這項奧斯卡研究由葛蘭素史克贊助和資助，是英國衞生和社會保障部(Department Of Health And Social Care)獲得緊急公共衞生研究地位的幾項研究之一。這項研究的縮寫是奧蒂利瑪在新冠肺炎相關嚴重疾病中的應用。
The study is planned to be extended to more hospitals across the U.K., the Manchester University NHS Foundation Trust said.
曼徹斯特大學NHS基金會信託基金表示，這項研究計劃擴展到英國各地的更多醫院。
Write to Adriano Marchese at adriano.marchese@wsj.com
寫信給Adriano Marchese：adriano.marchese@wsj.com
(END) Dow Jones Newswires
(完)道瓊斯通訊社
September 27, 2020 19:01 ET (23:01 GMT)
2020年9月27日美國東部時間19：01(格林尼治標準時間23：01)
Copyright (c) 2020 Dow Jones & Company, Inc.
版權所有(C)2020道瓊斯公司。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧